RIP1 post-translational modifications.


Journal

The Biochemical journal
ISSN: 1470-8728
Titre abrégé: Biochem J
Pays: England
ID NLM: 2984726R

Informations de publication

Date de publication:
13 05 2022
Historique:
received: 19 02 2022
revised: 13 04 2022
accepted: 19 04 2022
entrez: 6 5 2022
pubmed: 7 5 2022
medline: 11 5 2022
Statut: ppublish

Résumé

Receptor interacting protein 1 (RIP1) kinase is a critical regulator of inflammation and cell death signaling, and plays a crucial role in maintaining immune responses and proper tissue homeostasis. Mounting evidence argues for the importance of RIP1 post-translational modifications in control of its function. Ubiquitination by E3 ligases, such as inhibitors of apoptosis (IAP) proteins and LUBAC, as well as the reversal of these modifications by deubiquitinating enzymes, such as A20 and CYLD, can greatly influence RIP1 mediated signaling. In addition, cleavage by caspase-8, RIP1 autophosphorylation, and phosphorylation by a number of signaling kinases can greatly impact cellular fate. Disruption of the tightly regulated RIP1 modifications can lead to signaling disbalance in TNF and/or TLR controlled and other inflammatory pathways, and result in severe human pathologies. This review will focus on RIP1 and its many modifications with an emphasis on ubiquitination, phosphorylation, and cleavage, and their functional impact on the RIP1's role in signaling pathways.

Identifiants

pubmed: 35522161
pii: 231273
doi: 10.1042/BCJ20210725
doi:

Substances chimiques

Inhibitor of Apoptosis Proteins 0
Receptor-Interacting Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

929-951

Informations de copyright

© 2022 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Auteurs

Eugene Varfolomeev (E)

Department of Early Discovery Biochemistry, Genentech, South San Francisco, CA 94110, U.S.A.

Domagoj Vucic (D)

Department of Early Discovery Biochemistry, Genentech, South San Francisco, CA 94110, U.S.A.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH